Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Apatinib in Soft Tissue Sarcoma
NCT03711279Phase 2Terminated
- Sponsor
- Hengrui
- Start
- Nov 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in soft tissue sarcoma (STS), sponsored by Hengrui. Started Nov 2018; status: terminated.
02
Drugs
camrelizumabRivoceranib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03711279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03711279.